Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethacizine (also known as ethacyzine) is a class Ic antiarrhythmic agent, structurally related to moracizine. It is primarily used in Russia and some other Commonwealth of Independent States (CIS) countries for the management of severe and/or refractory ventricular and supraventricular arrhythmias, particularly those associated with organic heart disease. Ethacizine is also indicated for the treatment of refractory tachycardia linked to Wolff–Parkinson–White syndrome. Its mechanism of action involves blocking cardiac sodium channels, which suppresses retrograde stimulus conduction along the fast pathway of the atrioventricular node, thereby controlling or preventing paroxysms of atrioventricular nodal tachycardia[1][4][6][7]. The drug belongs to the phenothiazines chemical class and is administered orally[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethacizine.